The tumour suppressor gene p53 is a key regulator of the cell cycle. Loss of p53 function is the most commonly identi®ed genetic event in cancer, occurring in more than 50% of all human tumours (Hollstein et al., 1996) . The protein encoded by p53 gene is activated in response to DNA damaging agents such as cellular stress, hypoxia, ultraviolet light, and chemicals. Activated p53 triggers a G 1 cell cycle arrest to facilitate DNA excision repair prior to replication and cell division (Lane, 1992) and can also signal cells to enter programmed cell death or an apoptotic pathway, thereby eliminating cells with damaged DNA (Shaw et al., 1992) . The mechanism by which p53 controls cell growth is by its ability to act as a transcription factor, inducing the expression of a number of genes involved in cell cycle control including those encoding waf1, mdm2, GADD45, cyclin G, bax and IGF3 (Ko and Prives, 1996) .
Gene mutations within the DNA binding domain of p53 are the most prevalent mechanism of functional inactivation, occurring most frequently in the DNA binding domain of the protein (Cho et al., 1994) . Nonmutational functional inactivation of p53 by several mechanisms has also been reported. These include abnormal cytoplasmic compartmentalization/sequestration of p53 protein (Moll et al., 1992) and binding to overexpressed mdm2 protein which abrogates p53 mediated transactivation (Oliner et al., 1992) . Functional p53 can also be lost by the formation of complexes with proteins encoded by a number of transforming viruses, including, among others, Simian Virus 40, human adenovirus, and human papillomavirus type 16/18 (reviewed in Vousden, 1995) .
The complete cDNA sequences of human (ZakutHouri et al., 1985) , murine (Zakut-Houri et al., 1983) , feline (Okuda et al., 1994) , canine (Veldhoen and Milner, 1998) and bovine (Komori et al., 1996) p53 have been published. Partial sequences for equine (Pazzi et al., 1996) and asinine (Nasir and Reid, 1995) p53 have also been described. Despite the importance of the p53 gene in the control of the cell cycle and the development of cancer, the only published data regarding porcine p53 has been the localization of the gene on chromosome 12 (Rettenberger et al., 1993) . As yet there has been little incentive to study either the p53 status or the development of tumours in the pig due to its relatively short life-span in the commercial environment. If pig cells, tissues or organs are to be used in the treatment of humans, the p53 status of any such material, and the propensity of pig tissue to develop cancer, may become more important. The aims of this work were therefore to characterize the porcine p53 cDNA, and to examine whether some of the commercially available anti-p53 antibodies could be used to study the expression of porcine p53.
Primers were designed to amplify the complete porcine p53 cDNA from an alignment of all known p53 cDNA sequences. Porcine cDNA was synthesized by reverse transcription from the anti-sense primer. Following ampli®cation and electrophoresis, a faint band of the expected size for a putative p53 product was observed at approximately 1.2 Kbp (results not shown). Sequencing and subsequent analysis using the GCG group of programmes showed this product to be 1175 bp in length. After removal of the restriction sites present at the end of each primer, the total speci®c product length was 1163 bp, with a single open reading frame starting at the third nucleotide encoding a 386 amino acid protein (Figure 1 ). The predicted protein was therefore identical in length to bovine p53 but seven amino acids shorter than human p53.
Comparison with known p53 sequences from various mammalian species indicated that this was a novel p53 like product. At the nucleotide level sequence was 87% conserved to human p53 and 86% conserved to bovine p53. The sequence was also closely related (89%) to the partial sequence of equine p53 that was available for comparison. An amino acid sequence comparison also showed considerable homology between the various predicted p53 proteins (human 88%, bovine 86%, equine 91%). Highest conservation of residues was noted between amino acids 100 and 300, with greater divergence at the N and C terminals of the aligned p53 protein sequences (Figure 2 ). The level of conservation between porcine p53 and that of other species is in agreement with previous comparisons when a novel p53 product has been described. Five regions of p53 highly conserved during evolution have previously been identi®ed (Soussi et al., 1990) , and the predicted pig amino acid sequence is 98% Figure 1 The cDNA and predicted amino acid sequence of porcine p53. Start codon position 3, Stop codon 1161. Primer determined sequence highlighted. GenBank Accession No. AF098067. Sense (GGATCCCMATGSAGGAGYCRCAGT) and antisense (GAATTCTCAGTCTGAGTCAGGCC) primers were designed according to an alignment of all known p53 cDNA sequences. Total RNA was extracted from the Pig PBMCs and 2.0 mg of RNA converted into cDNA by reverse transcription from the antisense PCR primer. Porcine p53 was ampli®ed using the Advantage High Fidelity PCR kit (Clontech) with a 50 : 50 mix of the HF and cDNA buers. PCR products were cloned into the PCR-Blunt vector (Topo-Blunt Cloning Kit, Invitrogen) and three clones generated from independent PCRs sequenced in both directions. Sequences were analysed and compared using programmes in the GCG package (Devereux et al., 1984) conserved to the consensus sequence in these regions. There is a high degree of conservation of amino acid residues throughout the central region of the protein, which is the critical domain for DNA binding (Soussi and May, 1996) , and the site where the majority of mutations that inactivate p53 are clustered (Hollstein et al., 1991 (Hollstein et al., , 1996 .
The cloned cDNA sequence was inserted into a mammalian expression vector. Recombinant protein from in vitro transcription/translation reactions was separated according to size by SDS-polyacrylamide gel electrophoresis. Gels were electro-blotted to PVDF membrane and examined for the presence of recombinant p53 by one of four antibodies. The commercially Figure 2 Alignment of the p53 amino acid sequences of various species. Consensus sequence generated only where complete agreement exists. Putative binding sites of two cross-species reactive monoclonal antibodies are highlighted in grey. The position of ®ve domains highly conserved during evolution is noted by underlining of the consensus sequence and the appropriate Roman numeral (I ± V) available anti-p53 antibodies are raised against human or mouse p53 and in previous work have been shown to be poorly reactive with recombinant p53s of other species (Veldhoen and Milner, 1998) . The CM-1 polyclonal antibody detected both recombinant p53 produced by transcription/translation of the porcine p53/Pci-Neo construct and the positive control p53 (Figure 3 ). An identical result was obtained with the monoclonal anti-p53 antibody Ab-3. The Ab-1 monoclonal detected the positive control human p53 but not the recombinant porcine p53 product. Recombinant porcine and human p53 were not detected with the Ab-5 monoclonal by Western blotting (results not shown). None of the antibodies tested bound to the Pci-Neo alone transcription/ translation reaction in the 40 ± 60 kDa range. Some binding of the Ab-3 monoclonal to protein present in both translation reactions at about 80 kDa was noted.
These results were in line with expectations: Ab-3 binds to a linear epitope that is conserved between human and porcine p53, whereas the Ab-1 epitope has a single amino acid substitution (see Figure 2) . Although the Ab-5 antibody shows some cross-species reactivity and is known to bind bovine p53, its epitope is believed to be conformational, and therefore it is unlikely to be detected under the denaturing conditions of a Western blot. There was a clear size dierence between the recombinant porcine p53 and the recombinant human p53 used as a positive control on the Western blots, the estimated size of porcine p53 being 50 kDa. The predicted porcine protein is 7 amino acids shorter than the human protein. The deletion appears to have occurred in the proline rich amino terminal region, a domain of the protein that may be involved in mediating growth arrest (Ruaro et al., 1997) , and apoptosis (Sakamuro et al., 1997) .
Due to the husbandry and economics of the pig industry, the development of tumours, and the genetics of neoplasia in the pig have as yet received little consideration. There is however increasing interest in the use of pig organs, tissues and cells in the treatment of human diseases (Bach, 1998) . While the immunology and potential for inter-species disease transmission by xenotransplantation has already received considerable attention (Rogers et al., 1998) , there has been little consideration of the potential for tumour development in transplanted organs which may have been modi®ed to cause little or no immunological response in the recipient species. Knowledge of the porcine p53 cDNA sequence, and the ability to study the porcine p53 protein will allow the p53 status of the pig population, and involvement of p53 in porcine tumours, to be investigated.
Accession number
Genbank accession no. AF098067. Figure 3 Western Blot of recombinant porcine p53 expressed in vitro. Lane 1, Porcine p53 cDNA in Pci-Neo template; Lane 2, blank; Lane 3, Pci-Neo alone template; Lane 4, Blank; Lane 5, Human p53 Western Blot Standard (Oncogene). Porcine p53 sequence was sub-cloned into Pci-Neo (Promega) and recombinant protein was produced by the Single Tube Protein System 3 (Novagen). Control reactions consisted of transcription/translation from Pci-Neo alone. Each translation reaction was mixed with an equal volume of 26SDS ± PAGE loading dye, and analysed by SDS ± PAGE. Rainbow Full Range molecular weight marker (Amersham) was used to determine the size of expressed proteins and recombinant human p53 (Oncogene) as a positive control. Gels were electro-blotted to a PVDF membrane (Hybond-P, Amersham). Four anti-p53 antibodies, the CM-1 polyclonal (1 : 5000 Novocastra) and the Ab-1, Ab-3 and Ab-5 monoclonals (5 mg/ml Oncogene) were used to examine the blots for the presence of recombinant p53. Bound primary antibody was visualised with an appropriate peroxidase labelled secondary antibody, by the ECL detection system (Amersham)
